This was a phase @ , open-label , randomized trial of EMD @ @ mg/kg subcutaneously weekly plus cetuximab ( combination ) vs cetuximab monotherapy ( control ) in cetuximab-nave patients with R/M SCCHN who progressed on @ cytotoxic regimen .